STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

IMPACT
SENTIMENT
SAGE : Nasdaq BIIB : Nasdaq
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq ESALY : OTC
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
IMPACT
SENTIMENT
BIIB : Nasdaq
Scribe Therapeutics Expands Collaboration With Biogen to Second Target
IMPACT
SENTIMENT
SAGE : Nasdaq BIIB : Nasdaq
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
IMPACT
SENTIMENT
BIIB : Nasdaq
New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
IMPACT
SENTIMENT
IONS : Nasdaq BIIB : Nasdaq
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
clinical trial
IMPACT
SENTIMENT
BIIB : Nasdaq ESALY : OTC
LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Stock BIIB logo
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

#413 Ranked by Market Cap
#3170 Ranked by Stock Gains
N/A Ranked by Dividends

BIIB Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili